颅咽管瘤的手术治疗通常会导致体重快速急剧增加，从而导致下丘脑肥胖。集中于饮食、体力活动和不同类型药物的治疗常常提供不令人满意的结果。迄今为止，尚未有关于使用索马鲁肽（一种新型 1 型受体胰高血糖素样肽-1 激动剂）来限制肿瘤手术切除后体重增加的下丘脑肥胖 (HO) 数据的报道，尽管其功效已得到证实在肥胖症治疗中。在本病例报告中，我们在一名因颅咽管瘤手术干预而诱发 HO 的 18 岁患者中测试了索马鲁肽。在体重减轻和代谢参数改善方面发现了非常有利的治疗反应。我们的患者仅经过 6 个月的治疗，体重就减轻了 30 多公斤，这在 HO 文献中从未报道过。© 作者 2023。由牛津大学出版社代表内分泌学会出版。

Surgical treatment of craniopharyngioma often leads to a rapid and dramatic weight gain, leading to hypothalamic obesity. Treatment focused on the diet, physical activity, and different types of drugs have very often provided unsatisfactory results. To date, no data have been reported on hypothalamic obesity (HO) regarding the use of semaglutide, a novel type 1 receptor glucagon-like peptide-1 agonist, to limit body weight gain after surgical removal of a neoplasm, despite its already documented efficacy in obesity treatment. In this case report, we tested semaglutide in an 18-year-old patient with HO induced by a surgical intervention for craniopharyngioma. A very favorable treatment response was found in terms of body weight reduction and improvement in metabolic parameters. Our patient lost more than than 30 kg after only 6 months of therapy, which has never been reported before in the literature on HO.© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.